Nevertheless, these results could support the studies showing that the treatment of patients with hereditary hemochromatosis by Proton Pump Inhibitors (PPIs) is beneficial for the reduction in iron absorption and stores, which reduces the frequency of phlebotomy therapies [13,14]. Here, ATP4A is linked to hereditary hemochromatosis.